Showing results (321-330 of 401) with videos related to

Sort By:
Pageof 41
European Urology Oncology|April 22, 2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314Yi-Tsung Lu, Melissa Plets, Gareth Morrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
The Journal of Urology|December 30, 2022
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk StratificationYair Lotan, Jay D Raman, Badrinath Konety, et al.
European Urology|August 28, 2020
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial CarcinomaYung Lyou, Petros Grivas, Jonathan E Rosenberg, et al.
European Urology|October 8, 2025
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 StudySiamak Daneshmand, Renata Zaucha, James W F Catto, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.
Urologic Oncology|May 21, 2020
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) membersJustin T Matulay, William Tabayoyong, Jonathan J Duplisea, et al.
The Journal of Urology|October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study ComparisonsMeera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
European Urology|July 7, 2020
Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysisStephen B Williams, Marcus G K Cumberbatch, Ashish M Kamat, et al.
Pageof 41